Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTN - Palatin Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11)	1/12/2001 4:27:56 PM
From: keokalani'nui	Read Replies (3) \| Respond to of 142

Rick, I take it you did not go to ptn's presentation. I recall from the webcast (thinking I could listen to the reply I didn't take really good notes) the presenter's enthusiasm for an anti-inflammatory candidate. I forgot how he described the pathway, but it sounded (I'm as gullible as I'm undereducated!) promising. I believe this is it: Bioorg Med Chem Lett 1999 May 17;9(10):1469-74 Metallopeptide approach to the design of biologically active ligands: design of specific human neutrophil elastase inhibitors. Shi Y, Sharma S Palatin Technologies Inc., Edison Corporate Center, NJ 08837, USA. A series of compounds was designed to inhibit human neutrophil elastase utilizing a modified metallopeptide scheme developed in our laboratory termed metal-ion induced distinctive array of structures (MIDAS). These metallopeptides, synthesized by solution and solid-phase methods, exhibited excellent structural diversity and specificity in inhibiting human neutrophil elastase. PMID: 10360758, UI: 99287503 He also mentioned the satiety program and had some animal graphs. Your author was not capable of judging. He spent the most time on their metal binding substrate, peptide to pharmaceutical, smalmol drug develpment program (MIDAS)...singing the praises of its stability...though it sounded like it ends up a 'large' small molecule. One other stray thought. It may be in the filings, but I also recall him say that although Leutech is 'partnered,' ptn gets 50% of net sales . That's a filthy royalty if from someone also mftg and distributing--but I'm not sure about the details. Wish I could give you the kind of hard info you're looking for. --Wilder